Gastrointestinal Cancer News

CHICAGO — The occurrence of genetic alterations appeared to differ in extrapulmonary neuroendocrine carcinoma arising in the gastrointestinal tract and pancreas based on specific tumor site, according to study results presented at the ASCO Annual Meeting.

CHICAGO — The addition of IMAB362 to standard first-line chemotherapy improved survival without increasing toxicity, according to the results of the phase 2 FAST trial presented at the ASCO Annual Meeting.

CHICAGO — Nivolumab, with or without ipilimumab, appeared tolerable and demonstrated clinical activity for patients with microsatellite instability-high metastatic colorectal cancer, according to early results from the CheckMate 142 phase 2 study presented at the ASCO Annual Meeting.

CHICAGO — Patients with nine different tumor types benefitted from targeted therapies administered outside of current drug indications, according to the results of a basket study presented at the ASCO Annual Meeting.

Preoperative chemoradiotherapy conferred better survival outcomes than chemotherapy alone among patients with locally advanced esophagogastric junction adenocarcinoma, according to results of the phase 3 POET trial presented at the ASCO Annual Meeting.

CHICAGO — Liquid biopsy identified genomic alterations in patients with advanced solid tumors at a similar rate to traditional tumor biopsy, according to data presented at the ASCO Annual Meeting.

CHICAGO — The addition of capecitabine to standard adjuvant gemcitabine chemotherapy significantly extended survival of patients with resected pancreatic ductal adenocarcinoma, according to results of a randomized phase 3 trial presented at the ASCO Annual Meeting.

Colorectal cancer has generally been classified as a sporadic disease because of a limited understanding about which patients will be diagnosed with it, but emerging evidence has identified several genetic predispositions for the disease, according to Zev Wainberg, MD, of UCLA.

Patients with cancer who undergo chemotherapy may be at elevated risk for a new primary cancer several years later.

Previous investigations conducted by the founders of the linear no-threshold model with respect to genetic effects and carcinogenesis represent “one of the greatest misapprehensions and oversight failures within the scientific research community,” according to authors of a study review published in American Journal of Clinical Oncology.